Preparation and Characterization of Ibrutinib Amorphous Solid Dispersions: a Discussion of Interaction Force

[1]  R. Fausto,et al.  Enhanced Solid-State Stability of Amorphous Ibrutinib Formulations Prepared by Hot-Melt Extrusion. , 2020, International journal of pharmaceutics.

[2]  Xin Wei,et al.  Microcrystalline cellulose as an effective crystal growth inhibitor for the ternary Ibrutinib formulation. , 2020, Carbohydrate polymers.

[3]  Sravanthi Reddy Pailla,et al.  Fabrication of Ibrutinib Nanosuspension by Quality by Design Approach: Intended for Enhanced Oral Bioavailability and Diminished Fast Fed Variability , 2019, AAPS PharmSciTech.

[4]  M. Ansari,et al.  Enhanced Oral Bioavailability of Ibrutinib Encapsulated Poly (Lactic-co- Glycolic Acid) Nanoparticles: Pharmacokinetic Evaluation in Rats , 2019, Current Pharmaceutical Analysis.

[5]  Zhigui Su,et al.  Solubility and bioavailability enhancement study of lopinavir solid dispersion matrixed with a polymeric surfactant - Soluplus. , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[6]  W. Dong,et al.  Amorphous and humidity caking: A review , 2019, Chinese Journal of Chemical Engineering.

[7]  S. Paydaş.  Management of adverse effects/toxicity of ibrutinib. , 2019, Critical reviews in oncology/hematology.

[8]  Yuanfeng Wei,et al.  Further enhanced dissolution and oral bioavailability of docetaxel by coamorphization with a natural P‐gp inhibitor myricetin , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[9]  N. Pedge,et al.  Solubility and dissolution rate enhancement of ibuprofen by co-milling with polymeric excipients , 2018 .

[10]  Michael L. Wang,et al.  Four‐year follow‐up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL) , 2018, British journal of haematology.

[11]  Ping I. Lee,et al.  Enhanced delivery of fixed‐dose combination of synergistic antichagasic agents posaconazole‐benznidazole based on amorphous solid dispersions , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  Guilan Quan,et al.  Polymer–Surfactant System Based Amorphous Solid Dispersion: Precipitation Inhibition and Bioavailability Enhancement of Itraconazole , 2018, Pharmaceutics.

[13]  R. Williams,et al.  Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery - An update. , 2018, International journal of pharmaceutics.

[14]  S. Rohani,et al.  Solubility measurement and correlation of the form A of ibrutinib in organic solvents from 278.15 to 323.15 K , 2016 .

[15]  Dhara D. Bavishi,et al.  Spring and parachute: How cocrystals enhance solubility , 2016 .

[16]  Raj Suryanarayanan,et al.  Mechanism of amorphous itraconazole stabilization in polymer solid dispersions: role of molecular mobility. , 2014, Molecular pharmaceutics.

[17]  Zhenhai Zhang,et al.  Solid dispersion of berberine-phospholipid complex/TPGS 1000/SiO₂: preparation, characterization and in vivo studies. , 2014, International journal of pharmaceutics.

[18]  S. Onoue,et al.  Microenvironmental pH-modification to improve dissolution behavior and oral absorption for drugs with pH-dependent solubility , 2014, Expert opinion on drug delivery.

[19]  Yamei Chen,et al.  Ibrutinib and novel BTK inhibitors in clinical development , 2013, Journal of Hematology & Oncology.

[20]  Hywel D Williams,et al.  Strategies to Address Low Drug Solubility in Discovery and Development , 2013, Pharmacological Reviews.

[21]  Koichi Wada,et al.  Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. , 2011, International journal of pharmaceutics.

[22]  Ashwini Nangia,et al.  Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals , 2011 .

[23]  B. Sarmento,et al.  Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. , 2007, Drug discovery today.

[24]  V. Stella,et al.  Prodrug strategies to overcome poor water solubility. , 2007, Advanced drug delivery reviews.

[25]  P York,et al.  Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. , 2007, Advanced drug delivery reviews.

[26]  James S. Taylor,et al.  Ideal copolymers and the second‐order transitions of synthetic rubbers. i. non‐crystalline copolymers , 2007 .

[27]  G. Betageri,et al.  Enhancement of dissolution of glyburide by solid dispersion and lyophilization techniques , 1995 .

[28]  Robert Simha,et al.  On a General Relation Involving the Glass Temperature and Coefficients of Expansion of Polymers , 1962 .

[29]  James S. Taylor,et al.  Ideal Copolymers and the Second-Order Transitions of Synthetic Rubbers. I. Noncrystalline Copolymers , 1953 .

[30]  G. Zografi,et al.  Coamorphous Active Pharmaceutical Ingredient-Small Molecule Mixtures: Considerations in the Choice of Coformers for Enhancing Dissolution and Oral Bioavailability. , 2018, Journal of pharmaceutical sciences.